SMi Group is proud to announce the return of Europe’s only Parallel Trade conference. Back for the 12th year, Parallel Trade returns to London on 6th-7th February 2018.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh